TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20426845

Group type: EXPERIMENTAL
Intervention: Insulin like growth factor-I (IGF-I) in patients with aSAH, mean IGF-I concentrations for days one to five were 8.1 +/- 3.5 nmol/l.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (elective aneurysm surgery), mean IGF-I concentrations for days one to five were 11.2 +/- 3.1 nmol/l.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 15d HRQoL in patients with aSAH was 0.81 +/- 0.16.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bayesian model factors for poor HRQoL in aSAH patients: use of statins prior to aSAH, hyponatremia, high SOFAmax, low cumulative IGF-I concentrations on days one to seven.
Number of subjects: 30
Study: 20427509

Group type: EXPERIMENTAL
Intervention: l-T(4) replacement therapy
Number of subjects: 11

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Hypothyroid patients (pooled data with controls)
Number of subjects: 11
Study: 20427701

Group type: EXPERIMENTAL
Intervention: Oral forodesine (200 mg/d) for up to 24 weeks
Number of subjects: 8

Group type: COMPARATOR
Intervention: In vitro incubations of CLL lymphocytes with 10 or 20 microM dGuo and forodesine (2 microM)
Number of subjects: 8
Study: 20427731

Group type: EXPERIMENTAL
Intervention: Binge-eating disorder
Number of subjects: 134
Study: 20429726

Group type: EXPERIMENTAL
Intervention: Lipiodol injection during flexible cystoscopy into the submucosa of the bladder wall
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Lipiodol injection
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Image-guided RT based on Lipiodol
Number of subjects: 5
Study: 20429821

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/salmeterol 100/50 microg combination (FSC)
Number of subjects: 475

Group type: COMPARATOR
Intervention: Fluticasone propionate 100 microg (FP)
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Both treatments (FSC and FP)
Number of subjects: 475
Study: 20429835

Group type: EXPERIMENTAL
Intervention: ARI + LI
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: ARI + VAL
Number of subjects: 283
Study: 20429886

Group type: EXPERIMENTAL
Intervention: New feeding protocol (PEP uP protocol)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard feeding protocol
Number of subjects: 50
Study: 20430469

Group type: EXPERIMENTAL
Intervention: Gefitinib 250 mg daily
Number of subjects: 45
Study: 20430905

Group type: EXPERIMENTAL
Intervention: Ketoconazole-modulated docetaxel (70 mg flat-dose)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Conventional-dosed docetaxel (75 mg/m²)
Number of subjects: 82
Study: 20430946

Group type: EXPERIMENTAL
Intervention: Higher baseline concentrations of free p-cresol
Number of subjects: 499
Study: 20431360

Group type: EXPERIMENTAL
Intervention: In-home visit with a regional nurse installer referencing a user's manual
Number of subjects: 109

Group type: COMPARATOR
Intervention: Unassisted patient use of the user's manual
Number of subjects: 109

Group type: COMPARATOR
Intervention: Telephone-based training not using regional nurse installers reinforcing the user's manual
Number of subjects: 109
Study: 20432813

Group type: EXPERIMENTAL
Intervention: One-year lifestyle intervention program (physical activity, nutrition course, behavioral therapy)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Substantial weight loss
Number of subjects: 18

Group type: COMPARATOR
Intervention: No substantial weight loss
Number of subjects: 18
Study: 20433539

Group type: EXPERIMENTAL
Intervention: Treatment for hypertension (specifics not provided)
Number of subjects: 1424

Group type: EXPERIMENTAL
Intervention: Untreated hypertension (BP >= 140/90 mm Hg)
Number of subjects: 1424

Group type: COMPARATOR
Intervention: Control of BP levels (not specified if treated or untreated)
Number of subjects: 1424
Study: 20433546

Group type: EXPERIMENTAL
Intervention: Home blood pressure monitoring (HBPM) compliance
Number of subjects: 377
Study: 20433715

Group type: EXPERIMENTAL
Intervention: Decentral data entry module using Googledocs
Number of subjects: 332
Study: 20433746

Group type: EXPERIMENTAL
Intervention: New electronic device for self-injection of subcutaneous interferon beta-1a, 44 mcg three times weekly, for 12 weeks.
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: New electronic device for self-injection of subcutaneous interferon beta-1a.
Number of subjects: 102
Study: 20434605

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) strength training for 5 months, 5 sessions per week, 20 minutes each session.
Number of subjects: 9
Study: 20435200

Group type: EXPERIMENTAL
Intervention: Endothelin-1 (ET-1) levels on admission
Number of subjects: 128
Study: 20435233

Group type: EXPERIMENTAL
Intervention: Caspofungin (70 mg for one dose, followed by 50 mg daily)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Micafungin (100 mg daily)
Number of subjects: 323
Study: 20435244

Group type: EXPERIMENTAL
Intervention: Leuprolide acetate 3.75-mg depot, administered as 6 monthly intramuscular injections.
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Leuprolide acetate 3.75-mg depot
Number of subjects: 160
Study: 20435654

Group type: EXPERIMENTAL
Intervention: NAVA with PEEPhigh (20 cm H2O)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: NAVA with PEEP1 (1 cm H2O)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: NAVA with varying PEEP levels
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: NAVA with PEEP changes
Number of subjects: 20
Study: 20435659

Group type: EXPERIMENTAL
Intervention: Upper-respiratory viral infections detected during AECOPD (RT-PCR for 14 respiratory viruses)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Upper-respiratory viral infections detected after recovery
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Procalcitonin and C-reactive protein levels during AECOPD
Number of subjects: 86
Study: 20435798

Group type: EXPERIMENTAL
Intervention: Perioperative hyperglycemia
Number of subjects: 3184
Study: 20437315

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 105
Study: 20438892

Group type: EXPERIMENTAL
Intervention: Megachannel prototype
Number of subjects: 41
Study: 20438900

Group type: EXPERIMENTAL
Intervention: Endoscopic resection of colon polyps with full-thickness closure using a novel needle and T-tag tissue apposition system (TAS) under laparoscopic observation.
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Colonoscopy at 3-month follow-up.
Number of subjects: 19
Study: 20439622

Group type: EXPERIMENTAL
Intervention: Eliglustat tartrate (Genz-112638) administered twice daily at 50- or 100-mg doses based on plasma drug concentrations.
Number of subjects: 26
Study: 20442368

Group type: EXPERIMENTAL
Intervention: WT1 mutated (WT1mut) patients
Number of subjects: 243

Group type: COMPARATOR
Intervention: WT1 wild-type (WT1wt) patients
Number of subjects: 243
Study: 20442365

Group type: EXPERIMENTAL
Intervention: Cytarabine-based induction therapy followed by 1 consolidation
Number of subjects: 909
Study: 20442387

Group type: EXPERIMENTAL
Intervention: Early outpatient follow-up within 7 days after discharge from heart failure hospitalization (hospital in the second quartile of early follow-up)
Number of subjects: 30136

Group type: EXPERIMENTAL
Intervention: Early outpatient follow-up within 7 days after discharge from heart failure hospitalization (hospital in the third quartile of early follow-up)
Number of subjects: 30136

Group type: EXPERIMENTAL
Intervention: Early outpatient follow-up within 7 days after discharge from heart failure hospitalization (hospital in the fourth quartile of early follow-up)
Number of subjects: 30136

Group type: COMPARATOR
Intervention: Lowest quartile of early follow-up (control group)
Number of subjects: 30136
Study: 20442435

Group type: EXPERIMENTAL
Intervention: Nocturnal ventilation and oxygen saturation monitoring during ascent
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Repeated recordings at 4,497 m and 5,533 m
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Correlation analysis of periodic breathing cycles
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Acute mountain sickness scores
Number of subjects: 34
Study: 20443734

Group type: EXPERIMENTAL
Intervention: HIV testing at baseline and follow-up after 1 month
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Prevalence of acute HIV infection
Number of subjects: 228
Study: 20444270

Group type: EXPERIMENTAL
Intervention: Experimental endotoxemia (2 ng/kg Escherichia coli lipopolysaccharide [LPS])
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 15
Study: 20444959

Group type: EXPERIMENTAL
Intervention: Breakfast (500 kcal, 21 g protein)
Number of subjects: 21

Group type: COMPARATOR
Intervention: No breakfast (control group)
Number of subjects: 21
Study: 20445181

Group type: EXPERIMENTAL
Intervention: bar-code eMAR
Number of subjects: 14041

Group type: COMPARATOR
Intervention: No bar-code eMAR
Number of subjects: 14041
Study: 20446946

Group type: EXPERIMENTAL
Intervention: Aspirin plus clopidogrel (dual antiplatelet therapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin (single antiplatelet therapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aggressive blood pressure targets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual blood pressure targets
Number of subjects: 0
Study: 20447528

Group type: EXPERIMENTAL
Intervention: MR-proANP (≥120 pmol/l)
Number of subjects: 1641

Group type: EXPERIMENTAL
Intervention: MR-proADM
Number of subjects: 1641

Group type: COMPARATOR
Intervention: BNP
Number of subjects: 1641

Group type: COMPARATOR
Intervention: NT-proBNP
Number of subjects: 1641

Group type: EXPERIMENTAL
Intervention: None of the biomarkers
Number of subjects: 1641
Study: 20448073

Group type: EXPERIMENTAL
Intervention: High serum FGF-23 levels
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: High serum FGF-23 and PTH levels
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Increased FGF-23 and phosphate, decreased 25(OH)D
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Serum phosphate levels
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: FGF-23 and PTH levels
Number of subjects: 125
Study: 20448094

Group type: EXPERIMENTAL
Intervention: D-dimer(+) and etCO(2)/O(2)(+)
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: D-dimer(+) and etCO(2)/O(2)(-)
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: etCO(2)/O(2) less than 0.28
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: etCO(2)/O(2) greater than 0.45
Number of subjects: 495
Study: 20448468

Group type: EXPERIMENTAL
Intervention: dTpa-IPV
Number of subjects: 415
Study: 20453640

Group type: EXPERIMENTAL
Intervention: Radial approach (169 patients)
Number of subjects: 1650

Group type: COMPARATOR
Intervention: Transfemoral approach (FEM) (917 patients)
Number of subjects: 1650

Group type: EXPERIMENTAL
Intervention: Both groups (Abciximab administered in 1086 patients)
Number of subjects: 1650
Study: 20456292

Group type: EXPERIMENTAL
Intervention: Injecting drugs
Number of subjects: 914

Group type: EXPERIMENTAL
Intervention: Using illegal drugs before or during sex
Number of subjects: 914

Group type: EXPERIMENTAL
Intervention: Having any US clients
Number of subjects: 914
Study: 20457555

Group type: EXPERIMENTAL
Intervention: Computer-assisted health-risk assessment tool
Number of subjects: 10
Study: 20457766

Group type: EXPERIMENTAL
Intervention: hFABP
Number of subjects: 1298
Study: 20457959

Group type: EXPERIMENTAL
Intervention: Dopamine agonist treatment
Number of subjects: 3090

Group type: COMPARATOR
Intervention: Pramipexole
Number of subjects: 3090

Group type: COMPARATOR
Intervention: Ropinirole
Number of subjects: 3090

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 3090
Study: 20457974

Group type: EXPERIMENTAL
Intervention: African descent (AD)
Number of subjects: 648

Group type: COMPARATOR
Intervention: European descent (ED)
Number of subjects: 648
Study: 20457975

Group type: EXPERIMENTAL
Intervention: Standard automated perimetry tests
Number of subjects: 760

Group type: EXPERIMENTAL
Intervention: Short-wavelength automated perimetry and frequency-doubling technology tests
Number of subjects: 760
Study: 20458050

Group type: EXPERIMENTAL
Intervention: Cediranib (45 mg/d)
Number of subjects: 31
Study: 20458532

Group type: EXPERIMENTAL
Intervention: Mutation-negative women from BRCA1/2-positive families
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Adjustment for possible reduction in breast cancer risk due to oophorectomy
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Women with at least one first-degree relative with breast cancer
Number of subjects: 395
Study: 20459721

Group type: EXPERIMENTAL
Intervention: Doripenem
Number of subjects: 625

Group type: COMPARATOR
Intervention: Comparators (piperacillin/tazobactam and imipenem)
Number of subjects: 625

Group type: COMPARATOR
Intervention: Comparators
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: Doripenem (in patients with P. aeruginosa at baseline)
Number of subjects: 625

Group type: COMPARATOR
Intervention: Comparators (in patients with P. aeruginosa at baseline)
Number of subjects: 625
Study: 20460644

Group type: EXPERIMENTAL
Intervention: Flavopiridol (40 mg/m2 IV bolus + 60 mg/m2 continuous IV infusion)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Flavopiridol (IVB/CIVI schedule)
Number of subjects: 24
Study: 20461357

Group type: EXPERIMENTAL
Intervention: Overfeeding by 5,200 kJ/day for 3 days
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Overfeeding by 5,200 kJ/day for 28 days
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Overfeeding for 3 days
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Overfeeding for 28 days
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Overfeeding for 3 and 28 days
Number of subjects: 41
Study: 20461780

Group type: EXPERIMENTAL
Intervention: Rituximab 1000 mg intravenously at baseline and week 2
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 20
Study: 20462451

Group type: EXPERIMENTAL
Intervention: Consultation services for HIV-positive individuals
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Fertility treatments
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Fertility investigations
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Sperm washing
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: In vitro fertilization
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Risk reduction techniques
Number of subjects: 23
Study: 20462662

Group type: EXPERIMENTAL
Intervention: 1% lidocaine with 1:200,000 epinephrine and 1:10 8.4% bicarbonate for local anesthesia
Number of subjects: 0
Study: 20463041

Group type: EXPERIMENTAL
Intervention: Habitual dietary ALA intake (1-g increment)
Number of subjects: 353

Group type: COMPARATOR
Intervention: Twin with 1-g higher ALA intake compared to co-twin
Number of subjects: 353
Study: 20463331

Group type: EXPERIMENTAL
Intervention: Subcutaneous ICD
Number of subjects: 137
Study: 20464118

Group type: EXPERIMENTAL
Intervention: Corneal wavefront-guided PRK with 0.02% mitomycin-C
Number of subjects: 60
Study: 20465593

Group type: EXPERIMENTAL
Intervention: Wireless motility capsule (WMC)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Radiopaque markers (ROM)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Overall device agreement
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Wireless motility capsule (WMC) and Radiopaque markers (ROM)
Number of subjects: 158
Study: 20466340

Group type: EXPERIMENTAL
Intervention: Interventricular mechanical delay (IVMD)
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Left ventricular filling time (LVFT)
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Health status responders (defined as DeltaKCCQ > or =+10 points)
Number of subjects: 324
Study: 20466342

Group type: EXPERIMENTAL
Intervention: Myocardial deformation imaging during LV pacing
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Myocardial deformation imaging with biventricular pacing
Number of subjects: 56

Group type: COMPARATOR
Intervention: Fluoroscopy
Number of subjects: 56
Study: 20466783

Group type: EXPERIMENTAL
Intervention: Insulin suppression of lipolysis
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Capillary density and ATpO2
Number of subjects: 21
Study: 20466853

Group type: EXPERIMENTAL
Intervention: Dasatinib 50 mg by mouth twice per day (or 100 mg daily) for the first 14 days of each of 8 cycles of hyper-CVAD, followed by maintenance daily dasatinib and monthly vincristine and prednisone for 2 years.
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Dasatinib with chemotherapy
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Dasatinib
Number of subjects: 35
Study: 20471615

Group type: EXPERIMENTAL
Intervention: Homeopathy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20471725

Group type: EXPERIMENTAL
Intervention: Butyrate enemas (100mM sodium butyrate, 60 ml daily for 20 days)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Saline (control group, n=18)
Number of subjects: 35
Study: 20472572

Group type: EXPERIMENTAL
Intervention: Shared leadership in high-performing teams
Number of subjects: 12

Group type: COMPARATOR
Intervention: Leadership behaviour in low-performing teams
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Distribution of leadership functions in high-performing teams
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Effectiveness of shared leadership
Number of subjects: 12
Study: 20472746

Group type: EXPERIMENTAL
Intervention: Intravitreal pegaptanib 0.3 mg administered every 6 weeks for 48 weeks
Number of subjects: 568
Study: 20472863

Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT) imaging during flexible bronchoscopy
Number of subjects: 5

Group type: COMPARATOR
Intervention: Conventional OCT scans of an endobronchial mass
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: OCT imaging
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: OCT scan features of malignancy
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Endobronchial imaging
Number of subjects: 5
Study: 20473060

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitor (SSRI) treatment
Number of subjects: 265
Study: 20473362

Group type: EXPERIMENTAL
Intervention: Novel techniques to assess risk for progression to multiple myeloma (MM) using serum-free light-chain analysis and immunophenotyping
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemoprevention of multiple myeloma (MM)
Number of subjects: 0
Study: 20477993

Group type: EXPERIMENTAL
Intervention: Liver transplantation (Lt) for CRC liver metastases
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repeat liver transplantation (Lt) for CRC liver metastases
Number of subjects: 0

Group type: COMPARATOR
Intervention: Liver transplantation (Lt) for CRC liver metastases (prior to 1995)
Number of subjects: 0
Study: 20478057

Group type: EXPERIMENTAL
Intervention: Low dose cyclophosphamide (300 mg/m2) followed by GM-CSF + GV1001 vaccinations
Number of subjects: 40
Study: 20478863

Group type: EXPERIMENTAL
Intervention: Endeavor zotarolimus-eluting stent (ZES)
Number of subjects: 8314
Study: 20484311

Group type: EXPERIMENTAL
Intervention: Asymmetric dimethylarginine (ADMA) levels in the highest quartile (> 0.84 mumol/l)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: ADMA as a predictor of MACE
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: ADMA levels
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Vascular function measures (arterial compliance and flow-mediated vasodilatation)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: ABI and walking time
Number of subjects: 133
Study: 20484443

Group type: EXPERIMENTAL
Intervention: Vitamin E (200 IU daily for 1 year)
Number of subjects: 500
Study: 20484456

Group type: EXPERIMENTAL
Intervention: n-3 long-chain polyunsaturated fatty acids (LCPUFAs) intake
Number of subjects: 2412

Group type: EXPERIMENTAL
Intervention: Fish consumption
Number of subjects: 2412

Group type: EXPERIMENTAL
Intervention: Low intake of n-3 LCPUFAs (< approximately 0.30 g/d)
Number of subjects: 2412
Study: 20484485

Group type: EXPERIMENTAL
Intervention: TT genotype
Number of subjects: 26

Group type: COMPARATOR
Intervention: AA genotype
Number of subjects: 26
Study: 20484486

Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 21
Study: 20484542

Group type: EXPERIMENTAL
Intervention: Regional left ventricular function assessment
Number of subjects: 356
Study: 20487048

Group type: EXPERIMENTAL
Intervention: Pregabalin (150-600 mg/day)
Number of subjects: 121
Study: 20488302

Group type: EXPERIMENTAL
Intervention: Overweight (BMI 25-29.9 kg/m²)
Number of subjects: 34309

Group type: EXPERIMENTAL
Intervention: Obesity (BMI ≥30 kg/m²)
Number of subjects: 34309

Group type: EXPERIMENTAL
Intervention: Participants becoming obese during the first 60 months
Number of subjects: 34309

Group type: EXPERIMENTAL
Intervention: Dynamic risk associated with BMI changes
Number of subjects: 34309

Group type: EXPERIMENTAL
Intervention: BMI increase of 1 kg/m²
Number of subjects: 34309
Study: 20489056

Group type: EXPERIMENTAL
Intervention: Thymectomy
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Rag1 mutations
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Thymus dysplasia
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Rag deficiency phenotype
Number of subjects: 1
Study: 20489392

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation of the quadriceps femoris muscle, 2-3 times a week for 6 weeks, in addition to an exercise program.
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation of the quadriceps femoris muscle.
Number of subjects: 64
Study: 20489620

Group type: EXPERIMENTAL
Intervention: Imatinib (dose escalation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modification of imatinib dose to achieve a target imatinib plasma level
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard imatinib dosing
Number of subjects: 0
Study: 20491740

Group type: EXPERIMENTAL
Intervention: 1200 IU vitamin D3 once daily for 12 months
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 20491780

Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin (1.3 mg/m²)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin (1.8 mg/m²)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin (both doses)
Number of subjects: 13
Study: 20492667

Group type: EXPERIMENTAL
Intervention: Taking Action Together intervention
Number of subjects: 0
Study: 20494615

Group type: EXPERIMENTAL
Intervention: 1987 survey
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: 1995 survey
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: 2007 survey
Number of subjects: 1000